Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate ...

Regeneron Pharmaceuticals said a late-stage study of the investigational cemdisiran monotherapy for generalized myasthenia gravis hit its key goals. Regeneron on Tuesday said the Phase 3 study in ...

On 26 August, Regeneron announced exciting results from Phase III clinical trial NIMBLE (NCT05070858) evaluating the efficacy and safety of pozelimab + cemdisiran combination therapy and cemdisiran ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) reported topline results from the phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway ...

Regeneron’s experimental siRNA therapy, cemdisiran, successfully met the main objectives in a Phase III trial for adults with generalized myasthenia gravis. In the 24‑week study, cemdisiran ...

Cemdisiran Phase 2 Study Design The Phase 2 trial will follow an adaptive study design with an initial cohort of 12 aHUS patients who are not currently treated with an anti-C5 monoclonal antibody.

Amid the increasingly competitive myasthenia gravis drug development space, siRNA candidate cemdisiran met phase III endpoints, with the monotherapy showing numerically higher results than a ...

Various statements in this release concerning Alnylam's future expectations, plans and prospects, including without limitation, Alnylam's views with respect to the potential for cemdisiran for the ...